


RAW SEQUENCE LISTING **ERROR REPORT**

BIOTECHNOLOGY
SYSTEMS
BRANCH



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/653,755

Source: 1648

Date Processed by STIC: 12/4/2000

RECEIVED

DEC 14 2000

TECH CENTER 1600, 2000

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin30help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER VERSION 3.0 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of-the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address:

<http://www.uspto.gov/web/offices/pac/checker>

Raw Sequence Listing Error Summary

ERROR DETECTED SUGGESTED CORRECTION

SERIAL NUMBER: 09/653,755

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 Wrapped Nucleics The number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 2 Wrapped Aminos The amino acid-number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 3 Incorrect Line Length The rules require that a line not exceed 72 characters in length. This includes spaces.
- 4 Misaligned Amino Acid The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs
Numbering between the numbering. It is recommended to delete any tabs and use spacing between the numbers.
- 5 Non-ASCII This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
- 6 Variable Length Sequence(s) contain n's or Xaa's which represented more than one residue.
As per the rules, each n or Xaa can only represent a single residue.
Please present the maximum number of each residue having variable length and
indicate in the (ix) feature section that some may be missing.
- 7 PatentIn ver. 2.0 "bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid
sequence(s) . Normally, PatentIn would automatically generate this section from the
previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section
to the subsequent amino acid sequence. This applies primarily to the mandatory <220>-<223>
sections for Artificial or Unknown sequences.
- 8 Skipped Sequences Sequence(s) missing. If intentional, please use the following format for each skipped sequence:
(OLD RULES) (2) INFORMATION FOR SEQ ID NO:X:
(i) SEQUENCE CHARACTERISTICS: (Do not insert any headings under "SEQUENCE CHARACTERISTICS")
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:X:
This sequence is intentionally skipped

Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
- 9 Skipped Sequences Sequence(s) missing. If intentional, please use the following format for each skipped sequence.
(NEW RULES) <210> sequence id number
 <400> sequence id number
 000
- 10 Use of n's or Xaa's Use of n's and/or Xaa's have been detected in the Sequence Listing.
(NEW RULES) Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 11 Use of <213> Organism Sequence(s) are missing this mandatory field or its response.
(NEW RULES)
- 12 Use of <220> Feature Sequence(s) are missing the <220> Feature and associated headings.
(NEW RULES) Use of <220> to <223> is MANDATORY if <213> ORGANISM is "Artificial" or "Unknown"
Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)
- 13 PatentIn ver. 2.0 "bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted
file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).
Instead, please use "File Manager" or any other means to copy file to floppy disk.

RECEIVED

DEC 14 2000

TECH CENTER 1600/2900

1648

RAW SEQUENCE LISTING
 PATENT APPLICATION: US/09/653,755

DATE: 12/04/2000
 TIME: 14:14:25

Input Set : A:\Mab4g10.app
 Output Set: N:\CRF3\12042000\I653755.raw

Does Not Comply
 Corrected Diskette Needed

1 <110> APPLICANT: Eisinger, Dominic P.
 4 Stiles, Lynn
 5 LaMarche, Arthur
 6 Jelinek, Thomas
 8 <120> TITLE OF INVENTION: Recombinant Monoclonal Antibody Specific for
 9 Phosphotyrosine-Containing Proteins
 11 <130> FILE REFERENCE: 724650-3
 C--> 13 <140> CURRENT APPLICATION NUMBER: US/09/653,755
 C--> 14 <141> CURRENT FILING DATE: 2000-08-10
 16 <160> NUMBER OF SEQ ID NOS: 12
 18 <170> SOFTWARE: PatentIn Ver. 2.1
 20 <210> SEQ ID NO: 1
 21 <211> LENGTH: 1365
 22 <212> TYPE: DNA
 23 <213> ORGANISM: Artificial Sequence
 25 <220> FEATURE:
 26 <223> OTHER INFORMATION: Description of Artificial Sequence: cDNA for heavy
 27 chain of recombinant antibody
 29 <400> SEQUENCE: 1
 30 gagggtccagc tgcacagtc tggacctgaa ctgggtgaagc ctggggcttc agtgatgata 60
 31 tctctcagga cttctgcata cacattcact gaaaacaccg tgcactgggt gaagcagagc 120
 32 catggagaga gccttgagtg gattggaggt attaatcctt actatgggtg tctatcttc 180
 33 agcccgaaagt tcaagggcaa ggccacattg actgtagaca agtctccag cacagcctac 240
 34 atggagctcc gcaqccctgac atctgaggat tctgcagtct attactgtgc aagaagggct 300
 35 ggggcgtact actttgacta ctggggccaa ggcaccactc tcacagtctc ctacgccaaa 360
 36 acaacacccc catcagtcata tccactggcc cctgggtgtg gagatacaac tggttcctcc 420
 37 gtgactctgg gatgcctggc caagggctac ttccctgagt cagtactgtg gacttggaa 480
 38 tctggatccc tgtccagcag tgtgcacacc tcccagctc tctgcagtc tggactctac 540
 39 actatgagca gctcagtgac tgtccctcc agcacctggc caagtcagac cgtcacctgc 600
 40 agcgttgctc acccagcccag cagcaccacg gtggacaaaa aacttgagcc cagcgggccc 660
 41 atttcaacaa tcaaccctg tctccatgc aaggagtgtc acaaatgccc agctcctaac 720
 42 ctcgagggtg gaccatccgt cttcatcttc cctccaaaata tcaaggatgt actcatgac 780
 43 tccctgacac ccaaggteac gtgtgtgtg gtggatgtga gcgaggatga cccagacgtc 840
 44 cagatcagct ggtttgtgaa caacgtggaa gtacacacag ctacagacaca aacctataga 900
 45 gaggattaca acagtactat ccgggtggtc agcacctcc ccatccagca ccaggactgg 960
 46 atgagtggca aggagltcaa atgcaaggtc aacaacaaa acotcccatc acccatcgag 1020
 47 agaaccatct caaaaattaa agggctagtc agagctccac aagtatacat cttgccgcca 1080
 48 ccagcagagc agttgtccag gaaagatgtc agtctcactt gcttggtcgt gggcttcaac 1140
 49 cctggagaca tcagtgtgga gtggaccagc aatgggcata cagaggagaa ctacaaggac 1200
 50 accgcaccag tcttgagtc tgacggttct tacttcatat atagcaagct caatatgaaa 1260
 51 acaagcaagt gggagaaaac agattccttc tcatgcaacg tgagacacga ggtctgaaa 1320
 52 aattactacc tgaagaagac catctcccg tctccgggt aatga 1365
 55 <210> SEQ ID NO: 2
 56 <211> LENGTH: 645
 57 <212> TYPE: DNA
 58 <213> ORGANISM: Artificial Sequence
 60 <220> FEATURE:

RECEIVED

DEC 14 2000

TECH CENTER 1600/2900

RAW SEQUENCE LISTING

DATE: 12/04/2000

PATENT APPLICATION: US/09/653,755

TIME: 14:14:25

Input Set : A:\Mab4g10.app

Output Set: N:\CRF3\12042000\I653755.raw

61 <223> OTHER INFORMATION: Description of Artificial Sequence:cDNA for light
62 chain of recombinant antibody

64 <400> SEQUENCE: 2

```

65 gaaaatgtgc taccacagtc tccagcaatc atgtctgcat ctccagggga aaaggtcacc 60
66 atgacctgca gggccagctc aaqgtgaagt tccagttact tgcactggta tcggcagaag 120
67 tcagggtgect cccccaact ctggatttat agcacatcca acttggtctc tggagtccct 180
68 gctcgttcca gtggcagtgg gtctgggacc tcttactctc tcacaatcag cagtgtggag 240
69 gctgaagatg ctgccactta ttactgccag cagtacagtg gttaccggac gttcgggtga 300
70 ggcaccaagc tggaaatcaa acgggctgat gctgcaccaa ctgtatccat cttccacca 360
71 tccagtgagc agttaacatc tggaggtgcc tcagtcgtgt gcttcttgaa caactctac 420
72 cccagaqaca tcaatgtcaa gtggaagatt gatggcagtg aacgacaaaa tgggtgctct 480
73 aacagttgga ctgatcagg cagcaagac agcacctaca gcattgagcag caccctcac 540
74 ttgaccaagg acgagtatga acgacataac agctatacct gtgagggcac tcacaagaca 600
75 tcaacttcac ccactgtcaa gagcttcaac aggaatgagt gttag 645

```

78 <210> SEQ ID NO: 3

79 <211> LENGTH: 1389

80 <212> TYPE: DNA

81 <213> ORGANISM: Artificial Sequence

83 <220> FEATURE:

84 <223> OTHER INFORMATION: Description of Artificial Sequence:cDNA for heavy

85 chain of recombinant antibody with 3'-histidine

86 tag sequence

88 <400> SEQUENCE: 3

```

89 gaggtccagc tgcacagtc tggacctgaa ctgggtgaagc ctggggcttc agtgatgata 60
90 tccttcagga ctctgcata cacattcact gaaaacaccg tgcactgggt gaagcagagc 120
91 catggagaga gccctgagtg gattggaggt ataatcctt actatggtyg ttctatcttc 180
92 agcccgaagt tcaagggcaa ggcacattg actgtagaca agtctccag cacagctac 240
93 atggagctcc gcagcctgac atctgaggat tctgcagtct attactgtgc aagaagggt 300
94 ggggctact actttgacta ctggggccaa ggcaccactc tcacagtctc ctacgccaaa 360
95 acaacacccc catcagcta tccactggcc cctgggtgtg gagatacaac tgggtccctc 420
96 gtgactctgg gatgcctggg caagggttac ttccttgagt cagtgaactgt gaactggaac 480
97 tctggatccc tgtccagcag tgtgcacacc tcccagctc tctgcagtc tggactctac 540
98 actatgagca gctcagtgac tgtccctcc agcacctgg caagtcagac cgtcacctgc 600
99 agcgttgctc acccagccag cagcaccag gtggacaaaa aacttgagcc cagcgggccc 660
100 atttcaacaa tcaacccctg tcttccatgc aaggagtgtc acaaatgccc agctcctaac 720
101 ctcgagggtg gaccatcctg ctctatcttc cctccaaata tcaaggatgt actcatgac 780
102 tccctgacac ccaaggctac gtgtgtgtg gtggatgtga gcgaggatga ccc. jacgc 840
103 cagatcagct ggtttgtgaa caacgtggaa gtacacacag ctacagacac aaccataga 900
104 gaggattaca acagtactat cgggtgtgtc agcacctcc ccattccaga ccaggactgg 960
105 atgagtggca aggagttcaa atgcaaggte aacaacaaa agctccctac acccatcgag 1020
106 agaaccatct caaaaattaa agggctagtc agagctccac aagtatacat cttgccgcc 1080
107 ccagcagagc agttgtccag gaaagatgtc agtctcactt gctgtgtcgt gggcttcaac 1140
108 cctggagaca tcagtgtgga gtggaccagc aatgggcata cagaggagaa ctacaaggac 1200
109 accgcaccag tcttgactc tgacggttct tacttcatat atagcaagct caatatgaaa 1260
110 acaagcaagt gggagaaaa acagttccttc tcatgcaacg tgagacacga ggtctgaaa 1320
111 aattactacc tgaagaagac catctcccgg tctccgggtg aaggtggcca tcaccaccat 1380
112 caccattga 1389

```

115 <210> SEQ ID NO: 4

116 <211> LENGTH: 454

RAW SEQUENCE LISTING DATE: 12/04/2000
 PATENT APPLICATION: US/09/653,755 TIME: 14:14:25

Input Set : A:\Mab4g10.app
 Output Set: N:\CRF3\12042000\I653755.raw

```

117 <212> TYPE: PRT
118 <213> ORGANISM: Artificial Sequence
120 <220> FEATURE:
121 <223> OTHER INFORMATION: Description of Artificial Sequence:Amino acid
122     sequence for heavy chain of recombinant antibody
124 <400> SEQUENCE: 4
125 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
126   1           5           10           15
128 Ser Val Met Ile Ser Cys Arg Thr Ser Ala Tyr Thr Phe Thr Glu Asn
129           20           25           30
131 Thr Val His Trp Val Lys Gln Ser His Gly Glu Ser Leu Glu Trp Ile
132           35           40           45
134 Gly Gly Ile Asn Pro Tyr Tyr Gly Gly Ser Ile Phe Ser Pro Lys Phe
135           50           55           60
137 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Thr Ala Tyr
138   65           70           75           80
140 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
141           85           90           95
143 Ala Arg Arg Ala Gly Ala Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
144           100          105          110
146 Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro
147           115          120          125
149 Leu Ala Pro Gly Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
150           130          135          140
152 Cys Leu Val Lys Gly Tyr Phe Pro Glu Ser Val Thr Val Thr Trp Asn
153 145           150          155          160
155 Ser Gly Ser Leu Ser Ser Ser Val His Thr Phe Pro Ala Leu Leu Gln
156           165          170          175
158 Ser Gly Leu Tyr Thr Met Ser Ser Ser Val Thr Val Pro Ser Ser Thr
159           180          185          190
161 Trp Pro Ser Gln Thr Val Thr Cys Ser Val Ala His Pro Ala Ser Ser
162           195          200          205
164 Thr Thr Val Asp Lys Lys Leu Glu Pro Ser Gly Pro Ile Ser Thr Ile
165           210          215          220
167 Asn Pro Cys Pro Pro Cys Lys Glu Cys His Lys Cys Pro Ala Pro Asn
168 225           230          235          240
170 Leu Glu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Asn Ile Lys Asp
171           245          250          255
173 Val Leu Met Ile Ser Leu Thr Pro Lys Val Thr Cys Val Val Val Asp
174           260          265          270
176 Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn
177           275          280          285
179 Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn
180           290          295          300
182 Ser Thr Ile Arg Val Val Ser Thr Leu Pro Ile Gln His Gln Asp Trp
183 305           310          315          320
185 Met Ser Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro
186           325          330          335
188 Ser Pro Ile Glu Arg Thr Ile Ser Lys Ile Lys Gly Leu Val Arg Ala

```

RAW SEQUENCE LISTING

DATE: 12/04/2000

PATENT APPLICATION: US/09/653,755

TIME: 14:14:25

Input Set : A:\Mab4g10.app

Output Set: N:\CRF3\12042000\I653755.raw

```

189          340          345          350
191 Pro Gln Val Tyr Ile Leu Pro Pro Pro Ala Glu Gln Leu Ser Arg Lys
192          355          360          365
194 Asp Val Ser Leu Thr Cys Leu Val Val Gly Phe Asn Pro Gly Asp Ile
195          370          375          380
197 Ser Val Glu Trp Thr Ser Asn Gly His Thr Glu Glu Asn Tyr Lys Asp
198 385          390          395          400
200 Thr Ala Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Ile Tyr Ser Lys
201          405          410          415
203 Leu Asn Met Lys Thr Ser Lys Trp Glu Lys Thr Asp Ser Phe Ser Cys
204          420          425          430
206 Asn Val Arg His Glu Gly Leu Lys Asn Tyr Tyr Leu Lys Lys Thr Ile
207          435          440          445
209 Ser Arg Ser Pro Gly Lys
210          450
213 <210> SEQ ID NO: 5
214 <211> LENGTH: 214
215 <212> TYPE: PRT
216 <213> ORGANISM: Artificial Sequence
218 <220> FEATURE:
219 <223> OTHER INFORMATION: Description of Artificial Sequence: Amino acid
220      sequence for light chain of recombinant antibody
222 <400> SEQUENCE: 5
223 Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
224 1          5          10          15
226 Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Val Ser Ser Ser
227          20          25          30
229 Tyr Leu His Trp Tyr Arg Gln Lys Ser Gly Ala Ser Pro Lys Leu Trp
230          35          40          45
232 Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
233          50          55          60
235 Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Val Glu
236 65          70          75          80
238 Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Gly Tyr Arg
239          85          90          95
241 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
242          100          105          110
244 Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
245          115          120          125
247 Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Arg Asp Ile
248          130          135          140
250 Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
251 145          150          155          160
253 Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
254          165          170          175
256 Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
257          180          185          190
259 Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
260          195          200          205

```

RAW SEQUENCE LISTING DATE: 12/04/2000
 PATENT APPLICATION: US/09/653,755 TIME: 14:14:25

Input Set : A:\Mab4g10.app
 Output Set: N:\CRF3\12042000\I653755.raw

```

262 Phe Asn Arg Asn Glu Cys
263      210
266 <210> SEQ ID NO: 6
267 <211> LENGTH: 462
268 <212> TYPE: PRT
269 <213> ORGANISM: Artificial Sequence
271 <220> FEATURE:
272 <223> OTHER INFORMATION: Description of Artificial Sequence:Amino acid
273      sequence for heavy chain of recombinant antibody
274      with C-terminal histidine tag sequence
276 <400> SEQUENCE: 6
277 Glu Val Gln Leu Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
278      1          5          10          15
280 Ser Val Met Ile Ser Cys Arg Thr Ser Ala Tyr Thr Phe Thr Glu Asn
281          20          25          30
283 Thr Val His Trp Val Lys Gln Ser His Gly Glu Ser Leu Glu Trp Ile
284          35          40          45
286 Gly Gly Ile Asn Pro Tyr Tyr Gly Gly Ser Ile Phe Ser Pro Lys Phe
287          50          55          60
289 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
290      65          70          75          80
292 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
293          85          90          95
295 Ala Arg Arg Ala Gly Ala Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
296          100         105         110
298 Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro
299          115         120         125
301 Leu Ala Pro Gly Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
302          130         135         140
304 Cys Leu Val Lys Gly Tyr Phe Pro Glu Ser Val Thr Val Thr Trp Asn
305      145         150         155         160
307 Ser Gly Ser Leu Ser Ser Ser Val His Thr Phe Pro Ala Leu Leu Gln
308          165         170         175
310 Ser Gly Leu Tyr Thr Met Ser Ser Ser Val Thr Val Pro Ser Ser Thr
311          180         185         190
313 Trp Pro Ser Gln Thr Val Thr Cys Ser Val Ala His Pro Ala Ser Ser
314          195         200         205
316 Thr Thr Val Asp Lys Lys Leu Glu Pro Ser Gly Pro Ile Ser Thr Ile
317          210         215         220
319 Asn Pro Cys Pro Pro Cys Lys Glu Cys His Lys Cys Pro Ala Pro Asn
320      225         230         235         240
322 Leu Glu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Asn Ile Lys Asp
323          245         250         255
325 Val Leu Met Ile Ser Leu Thr Pro Lys Val Thr Cys Val Val Val Asp
326          260         265         270
328 Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn
329          275         280         285
331 Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn
332          290         295         300

```

09/53,755

6

<210> 8

<211> 80

<212> DNA

<213> Artificial Sequence

see item 12 on Enn summary sheet

<400> 8

gccaccatgg attttctggt gcagattttc agcttcttgc taatcagtgc ctcagttgca 60

atgtccagag gagaaaatgt

80

RECEIVED

DEC 14 2000

TECH CENTER 1600/2900

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/653,755

DATE: 12/04/2000

TIME: 14:14:26

Input Set : A:\Mab4g10.app

Output Set: N:\CRF3\12042000\I653755.raw

L:13 M:270 C: Current Application Number differs, Replaced Application Number

L:14 M:271 C: Current Filing Date differs, Replaced Current Filing Date

L:384 M:258 W: Mandatory Feature missing, <220> FEATURE:

L:384 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION: